BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, cilt.23, ss.1242-1246, 2009 (SCI İndekslerine Giren Dergi)
Early diagnosis and proper treatment of latent tuberculosis infection (LTB1) in patients with end stage renal diseases (ESRD) is critical to reduce increased reactivation risk of LTB1. However; this condition is known to decrease responsiveness to the tubercidin skin test (TST). A new, diagnostic test [QuantiFERON-TB Gold in-tube (QFT-GIT)] has been developed using mycobacterium tuberculosis specific antigens for the identification of LTB1. We aimed to evaluate the two test methods among hemodialysis patients for their diagnostic usefulness.